Clinical safety of robenacoxib in cats with chronic musculoskeletal disease.

Jonathan N KingWolfgang SeewaldSophie Forster Gabriele Friton Derek E Adrian Benedict Duncan X Lascelles

Published in: Journal of veterinary internal medicine (2021)

Robenacoxib was not associated with increased risk of AEs compared to placebo when administered for 4 to 12 weeks to cats with CMSD. The generalizability of the results to general practice is limited by the fact that cases with severe and uncontrolled concomitant diseases were not included.

Keyphrases

general practice
primary care
early onset
drug induced
gestational age
phase iii
randomized controlled trial
preterm birth
placebo controlled